Wednesday , November 22 2017
Home / Technology & Devices

Technology & Devices

Boehringer Ingelheim Launches New Platform Offering Open Access to Many of its Best Molecules to Unlock Their Full Potential

INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and …

Read More »

Bayer Enters Potential Billion-Dollar Discovery Collaboration Agreement with PeptiDream

KAWASAKI, Japan–(BUSINESS WIRE)–PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG (“Bayer”)(ETR:BAYN). Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple targets of interest selected …

Read More »

Amgen Launches the Enbrel Mini Reusable Autoinjector That is Ergonomically Designed for Patients

THOUSAND OAKS, Calif., Nov. 17, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) announced that the ENBREL Mini™ with AutoTouch™ is now available in the United States (U.S.). Awarded the Arthritis Foundation Ease of UseSM Commendation, this new and innovative delivery system provides an additional administration option for appropriate ENBREL patients. The …

Read More »

NYU Stern Study Shows Significant Health Improvement in Diabetes Patients with Mobile Health Applications

NEW YORK–(BUSINESS WIRE)–New research “Empowering Patients Using Smart Mobile Health Platforms: Evidence from a Randomized Field Experiment,” from NYU Stern Professor Anindya Ghose and co-authors, Beibei Li of Carnegie Mellon University and Xitong Guo of the Harbin Institute of Technology, explores how emerging mobile health (mHealth) technologies can persuade chronic-disease patients to …

Read More »

FDA Unveils a Streamlined Path for the Authorization of Tumor Profiling Tests Alongside its Latest Product Action

The U.S. Food and Drug Administration today authorized Memorial Sloan Kettering Cancer Center’s (MSK) IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) tumor profiling test (assay), an in vitro diagnostic test that can identify a higher number of genetic mutations (biomarkers) that may be found in various cancers than any …

Read More »

Roche’s VENTANA MMR IHC Panel Receives FDA Clearance for Patients Diagnosed with Colorectal Cancer

TUCSON, Ariz., Nov. 14, 2017 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food & Drug Administration (FDA) clearance of the VENTANA MMR IHC Panel, which provides clinicians with a comprehensive group of immunohistochemistry (IHC) tests for patients diagnosed with colorectal cancer. The tests detect certain proteins …

Read More »

FDA Approves Pill with Sensor that Digitally Tracks If Patients Have Ingested Their Medication

The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, …

Read More »

Adaptive Collaborates with Amgen to Advance Development of the clonoSEQ Assay in Multiple Myeloma

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, a leader in combining next-generation sequencing (NGS) and sophisticated bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has entered into a collaboration agreement with Amgen to utilize Adaptive’s NGS-based clonoSEQ Assay in the Phase 3 CANDOR study, sponsored by Amgen in …

Read More »

Daiichi Sankyo & Glycotope Enter Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing

TOKYO and BASKING RIDGE, N.J., and BERLIN, Oct. 30, 2017 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have signed an option agreement for future strategic collaboration and licensing to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with …

Read More »

New Study: ‘Double Decker’ Antibody Technology Fights Cancer

JUPITER, Fla., Oct. 25, 2017 /PRNewswire-USNewswire/ — Scientists from the Florida campus of The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates (ADCs), using a versatile “double decker” technology that ties antibodies and a drug together to produce highly potent pharmaceuticals for cancer therapy. The new …

Read More »